RXST
RxSight, Inc.
RXST lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
RXST Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
RXST's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
RXST PE Valuation
RXST has no meaningful PE right now: it lost money over the past year.
RXST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RXST's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RXST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.41 |
| Q2 2026 | -$1.13 | -$0.34 |
| Q1 2026 | -$1.13 | -$0.47 |
| Q4 2025 | -$0.95 | -$0.24 |
| Q3 2025 | -$0.87 | -$0.06 |
| Q2 2025 | -$0.79 | +$0.21 |
| Q1 2025 | -$0.66 | +$0.58 |
| Q4 2024 | -$0.71 | +$0.70 |
RXST is still losing money, but far less than before: $1.28 per share over the past year, against $3.19 at its worst in late 2021.
RXST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -19% |
| Q2 2026 | $33.7M | +0.3% |
| Q1 2026 | $30.9M | -18% |
| Q4 2025 | $32.6M | -19% |
| Q3 2025 | $30.3M | -14% |
| Q2 2025 | $33.6M | -3.6% |
| Q1 2025 | $37.9M | +28% |
| Q4 2024 | $40.2M | +41% |
RXST's revenue has slid since its 2024 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | -35 points |
| Q2 2026 | -41% | +0.8 points |
| Q1 2026 | -58% | -30 points |
| Q4 2025 | -35% | -13 points |
| Q3 2025 | -40% | -14 points |
| Q2 2025 | -42% | -18 points |
| Q1 2025 | -28% | +8 points |
| Q4 2024 | -21% | +17 points |
RXST's operating margin was −75% last quarter, down 35 points from the same quarter a year ago.
RXST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44M | +$45.8M |
| Q2 2026 | -$11.5M | -$5.6M |
| Q1 2026 | -$11.7M | -$2.2M |
| Q4 2025 | -$2.3M | +$2.9M |
| Q3 2025 | -$1.8M | -$1.3M |
| Q2 2025 | -$5.9M | -$363K |
| Q1 2025 | -$9.4M | +$1.9M |
| Q4 2024 | -$5.1M | +$4.8M |
RXST's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
RXST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +215K shares |
| 1 year | +1.8% | +740K shares |
| 3 years | +17% | +6M shares |
| 5 years | +901% | +37.5M shares |
| Available history | +119% | +22.6M shares |
RXST has 42M diluted shares, up 1.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RXST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 0.3x | Very low |
| Q4 2020 | 0.5x | Very low |
RXST's net debt is less than a year of its operating earnings (EBITDA).
RXST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 22.2 | Neutral |
RXST's weekly RSI is 47 (neutral) and its Stochastic is 22 (neutral).
RXST PE vs Healthcare Sector
RXST has no meaningful PE right now: it lost money over the past year.
RXST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.81 | 12% above |
| 20 week MA | $5.49 | 2% below |
| 50 week MA | $6.88 | 22% below |
| 100 week MA | $11.9 | 55% below |
| 200 week MA | $24.9 | 78% below |
RXST has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 78% below its 200-week average.
RXST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.0 | $10.6 | -34% |
| 2022 | $10.6 | $11.9 | +12% |
| 2023 | $11.9 | $40.3 | +239% |
| 2024 | $40.3 | $34.2 | -15% |
| 2025 | $34.2 | $10.9 | -68% |
| 2026 YTD | $10.9 | $5.38 | -51% |
RXST's yearly returns have swung widely, from +239% in 2023 to −68% in 2025. It's down 51% so far in 2026.